Osman Zekioglu
Overview
Explore the profile of Osman Zekioglu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
67
Citations
385
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Xaligli G, Sancar C, Serin G, Akman L, Ozdemir N, Zekioglu O, et al.
J Obstet Gynaecol Res
. 2024 Sep;
50(10):1808-1812.
PMID: 39291759
Aims: Our research aims to shed light on the connection between histopathological differences that affect the prognosis of endometrial cancer and Doppler indices measured in the uterine arteries. Methods: Seventy-four...
2.
Onat I, Kocagoz R, Demirbugen Oz M, Yeniay L, Tiftikcioglu Y, Zekioglu O, et al.
Environ Toxicol Pharmacol
. 2024 Apr;
108:104433.
PMID: 38583790
We investigated possible associations between the internal concentrations of POPs and correlations between blood and tumor tissue concentrations in patients who underwent surgery for breast cancer and breast reduction as...
3.
Guzel D, Terek C, Besler A, Serin G, Onal Z, Akman L, et al.
Eur J Obstet Gynecol Reprod Biol
. 2024 Mar;
296:321-326.
PMID: 38518487
Objective: Our primary aim in this study is to define the clinical characteristics of patients with clear-cell ovarian carcinoma and evaluate the prognostic factors affecting survival. Study Design: Records of...
4.
Savas P, Serin G, Gursoy P, Zekioglu O, Ozdemir N
Pol J Pathol
. 2023 Sep;
74(2):65-74.
PMID: 37728465
This study aims to determine the prognostic significance of programmed cell death ligand 1 (PD-L1) expression and tumour-infiltrating lymphocytes (TILs) in triple- negative breast cancer (TNBC). PD-L1 expression and TIL...
5.
Kalkan H, Akman L, Serin G, Terek M, Zekioglu O, Ozsaran A
Histol Histopathol
. 2023 Jul;
39(5):565-571.
PMID: 37503793
Objectives: Endometrial cancer (EC) is the most commonly diagnosed gynecological cancer. Endometrial hyperplasia (EH) is a more common diagnosis than EC. Endometrial hyperplasia is found in approximately 1.5% of all...
6.
Gursoy M, Oktay A, Aslan O, Zekioglu O
Eur J Breast Health
. 2023 Apr;
19(2):140-147.
PMID: 37025575
Objective: Tumour regression is defined as continuity of changes leading to the elimination of a neoplastic population and is reflected as periductal fibrosis and intraductal tumour attenuation. The aim of...
7.
Aslan O, Oktay A, Katuk B, Erdur R, Dikenelli O, Yeniay L, et al.
Diagn Interv Radiol
. 2023 Mar;
29(2):260-267.
PMID: 36987868
Purpose: High-risk breast lesions (HRLs) are associated with future risk of breast cancer. Considering the pathological subtypes, malignancy upgrade rate differs according to each subtype and depends on various factors...
8.
Gursoy M, Aslan O, Oktay Alfatli A, Zekioglu O, Goktepe B
Diagn Interv Radiol
. 2023 Mar;
29(1):53-58.
PMID: 36959768
Purpose: The diagnosis and surgical treatment delays that occurred during the coronavirus disease-2019- (COVID-19) pandemic may have affected breast cancer presentation. This study aimed to determine whether there was a...
9.
Ucan E, Alpaydin A, Gunduz Karayazi D, Kapkac M, Takar B, Zekioglu O, et al.
Tuberk Toraks
. 2022 Sep;
70(3):271-278.
PMID: 36164951
Introduction: Tuberculosis (TB) mastitis is a rare form of granulomatous mastitis. We aimed to evaluate the clinical characteristics and prognosis of patients diagnosed with TB mastitis. Materials And Methods: A...
10.
Gul A, Doskaya M, Can H, Karakavuk M, Anil-Inevi M, Saglam-Metiner P, et al.
Vaccine
. 2022 Mar;
40(16):2409-2419.
PMID: 35305824
Breast cancer was ranked first in global cancer incidence in 2020, and HER2 overexpression in breast cancer accounts for 20-30% of breast cancer patients. Current therapeutic strategies increase the survival...